Table A3.
Multivariable Cox Proportional Hazards Model of 10-Year Survival Across All Posterior Fossa Ependymoma
| Variable | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| GENE cohort (PFS, n = 304; OS, n =3 05) | ||||
| Subgroup EPN_PFA | 2.61 (1.04 to 6.53) | .04 | 5.26 (1.17 to 23.60) | .03 |
| Age | 0.96 (0.93 to 0.99) | .005 | 0.96 (0.92 to 1.00) | .03 |
| Incomplete resection | 1.90 (1.33 to 2.72) | < .001 | 2.49 (1.61 to 3.87) | < .001 |
| Adjuvant first-line radiation | 0.29 (0.20 to 0.43) | < .001 | 0.27 (0.17 to 0.43) | < .001 |
| Adjuvant first-line chemotherapy | 1.01 (0.69 to 1.47) | .96 | 0.75 (0.47 to 1.22) | .25 |
| Male | 1.16 (0.83 to 1.61) | .40 | 1.20 (0.79 to 1.82) | .40 |
| CERN cohort (PFS, n = 120; OS, n = 120) | ||||
| Subgroup EPN_PFA | 2.08 (0.65 to 6.66) | .22 | 7.52 (1.09 to 51.67) | .04 |
| Age | 1.00 (0.97 to 1.03) | .89 | 1.00 (0.96 to 1.05) | .73 |
| Incomplete resection | 1.59 (0.91 to 2.79) | .10 | 1.82 (0.86 to 3.85) | .12 |
| Adjuvant first-line radiation | 0.70 (0.43 to 1.14) | .15 | 0.67 (0.53 to 1.28) | .22 |
| Adjuvant first-line chemotherapy | 0.95 (0.51 to 1.79) | .88 | 0.77 (0.35 to 1.68) | .51 |
| Male | 1.17 (0.73 to 1.90) | .51 | 2.02 (1.01 to 4.04) | .05 |
| St Jude RT1 cohort (PFS, n = 112; OS, n = 112) | ||||
| Subgroup EPN_PFA | 2.87 (0.31 to 26.73) | .35 | 4.68 (0.40 to 662.59) | .25 |
| Age | 1.00 (0.90 to 1.11) | 1.00 | 1.05 (0.91 to 1.18) | .47 |
| Incomplete resection | 2.77 (1.42 to 5.38) | .003 | 3.49 (1.56 to 7.45) | .003 |
| Male | 2.42 (1.25 to 4.67) | .009 | 3.16 (1.38 to 8.30) | .006 |
| Burdenko cohort (PFS, n = 241; OS, n = 241) | ||||
| Subgroup EPN_PFA | 2.46 (0.97 to 6.24) | .06 | 2.90 (0.54 to 15.55) | .21 |
| Age | 0.99 (0.96 to 1.02) | .63 | 0.98 (0.93 to 1.04) | .52 |
| Incomplete resection | 2.00 (1.40 to 2.84) | < .001 | 2.01 (1.18 to 3.42) | .01 |
| Adjuvant first-line radiation | 1.09 (0.73 to 1.64) | .66 | 1.10 (0.60 to 2.03) | .75 |
| Adjuvant first-line chemotherapy | 1.01 (0.66 to 1.54) | .96 | 1.31 (0.67 to 2.54) | .43 |
| Male | 1.10 (0.76 to 1.58) | .62 | 0.84 (0.49 to 1.42) | .51 |
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.